Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 20 entries
Sorted by: Best Match Show Resources per page
Markers of disease.

Science (New York, N.Y.)

Helzlsouer KJ.
PMID: 17782057
Science. 1993 Nov 12;262(5136):1082-3. doi: 10.1126/science.262.5136.1082.

No abstract available.

Cite
Helzlsouer KJ. Markers of disease. Science. 1993;262(5136):1082-3doi: 10.1126/science.262.5136.1082.
Helzlsouer, K. J. (1993). Markers of disease. Science (New York, N.Y.), 262(5136), 1082-3. https://doi.org/10.1126/science.262.5136.1082
Helzlsouer, K J. "Markers of disease." Science (New York, N.Y.) vol. 262,5136 (1993): 1082-3. doi: https://doi.org/10.1126/science.262.5136.1082
Helzlsouer KJ. Markers of disease. Science. 1993 Nov 12;262(5136):1082-3. doi: 10.1126/science.262.5136.1082. PMID: 17782057.
Copy Download .nbib Format: NLM
Effects of repeated freeze-thaw cycles on concentrations of cholesterol, micronutrients, and hormones in human plasma and serum.

American journal of epidemiology

Comstock GW, Burke AE, Norkus EP, Gordon GB, Hoffman SC, Helzlsouer KJ.
PMID: 18820276
Am J Epidemiol. 2008 Oct 01;168(7):827-30. doi: 10.1093/aje/kwn327.

No abstract available.

Cite
Comstock GW, Burke AE, Norkus EP, et al. Effects of repeated freeze-thaw cycles on concentrations of cholesterol, micronutrients, and hormones in human plasma and serum. Am J Epidemiol. 2008;168(7):827-30doi: 10.1093/aje/kwn327.
Comstock, G. W., Burke, A. E., Norkus, E. P., Gordon, G. B., Hoffman, S. C., & Helzlsouer, K. J. (2008). Effects of repeated freeze-thaw cycles on concentrations of cholesterol, micronutrients, and hormones in human plasma and serum. American journal of epidemiology, 168(7), 827-30. https://doi.org/10.1093/aje/kwn327
Comstock, George W, et al. "Effects of repeated freeze-thaw cycles on concentrations of cholesterol, micronutrients, and hormones in human plasma and serum." American journal of epidemiology vol. 168,7 (2008): 827-30. doi: https://doi.org/10.1093/aje/kwn327
Comstock GW, Burke AE, Norkus EP, Gordon GB, Hoffman SC, Helzlsouer KJ. Effects of repeated freeze-thaw cycles on concentrations of cholesterol, micronutrients, and hormones in human plasma and serum. Am J Epidemiol. 2008 Oct 01;168(7):827-30. doi: 10.1093/aje/kwn327. PMID: 18820276.
Copy Download .nbib Format: NLM
Applying the Strategic Planning Process to a Large Research Consortium: The Example of the National Cancer Institute Cohort Consortium.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Harvey CE, Gapstur SM, Pottinger CA, Elena JW, Helzlsouer KJ.
PMID: 34446473
Cancer Epidemiol Biomarkers Prev. 2021 Oct;30(10):1769-1774. doi: 10.1158/1055-9965.EPI-21-0513. Epub 2021 Aug 26.

Strategic planning is conducted by many organizations to systematically evaluate and assess their current state, establish or update their mission and/or goals, and identify strategies and activities to achieve the goals. The National Cancer Institute (NCI) Cohort Consortium is...

Cite
Harvey CE, Gapstur SM, Pottinger CA, et al. Applying the Strategic Planning Process to a Large Research Consortium: The Example of the National Cancer Institute Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2021;30(10):1769-1774doi: 10.1158/1055-9965.EPI-21-0513.
Harvey, C. E., Gapstur, S. M., Pottinger, C. A., Elena, J. W., & Helzlsouer, K. J. (2021). Applying the Strategic Planning Process to a Large Research Consortium: The Example of the National Cancer Institute Cohort Consortium. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(10), 1769-1774. https://doi.org/10.1158/1055-9965.EPI-21-0513
Harvey, Chinonye E, et al. "Applying the Strategic Planning Process to a Large Research Consortium: The Example of the National Cancer Institute Cohort Consortium." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,10 (2021): 1769-1774. doi: https://doi.org/10.1158/1055-9965.EPI-21-0513
Harvey CE, Gapstur SM, Pottinger CA, Elena JW, Helzlsouer KJ. Applying the Strategic Planning Process to a Large Research Consortium: The Example of the National Cancer Institute Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2021 Oct;30(10):1769-1774. doi: 10.1158/1055-9965.EPI-21-0513. Epub 2021 Aug 26. PMID: 34446473.
Copy Download .nbib Format: NLM
Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland.

PPAR research

Gallicchio L, Kalesan B, Huang HY, Strickland P, Hoffman SC, Helzlsouer KJ.
PMID: 18288282
PPAR Res. 2008;2008:276581. doi: 10.1155/2008/276581.

The primary aim of this study was to examine prospectively the associations between 5 peroxisome proliferator-activated receptor (PPAR) single nucleotide polymorphisms (SNPs) and cardiovascular morbidity and mortality in a community-based cohort study in Washington County, Maryland. Data were analyzed...

Cite
Gallicchio L, Kalesan B, Huang HY, et al. Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland. PPAR Res. 2008;2008:276581doi: 10.1155/2008/276581.
Gallicchio, L., Kalesan, B., Huang, H. Y., Strickland, P., Hoffman, S. C., & Helzlsouer, K. J. (2008). Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland. PPAR research, 2008276581. https://doi.org/10.1155/2008/276581
Gallicchio, L, et al. "Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland." PPAR research vol. 2008 (2008): 276581. doi: https://doi.org/10.1155/2008/276581
Gallicchio L, Kalesan B, Huang HY, Strickland P, Hoffman SC, Helzlsouer KJ. Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland. PPAR Res. 2008;2008:276581. doi: 10.1155/2008/276581. PMID: 18288282; PMCID: PMC2233806.
Copy Download .nbib Format: NLM
Updating the landscape of direct-to-consumer pharmacogenomic testing.

Pharmacogenomics and personalized medicine

Filipski KK, Murphy JD, Helzlsouer KJ.
PMID: 28860839
Pharmgenomics Pers Med. 2017 Aug 22;10:229-232. doi: 10.2147/PGPM.S140461. eCollection 2017.

Pharmacogenomics has identified important drug-gene interactions that affect the safety and efficacy of medications. Direct-to-consumer genetic testing, when first introduced, included some pharmacogenomic-related genes. The current landscape of pharmacogenomic direct-to-consumer testing is reviewed. Prior published reviews of the literature...

Cite
Filipski KK, Murphy JD, Helzlsouer KJ. Updating the landscape of direct-to-consumer pharmacogenomic testing. Pharmgenomics Pers Med. 2017;10:229-232doi: 10.2147/PGPM.S140461.
Filipski, K. K., Murphy, J. D., & Helzlsouer, K. J. (2017). Updating the landscape of direct-to-consumer pharmacogenomic testing. Pharmacogenomics and personalized medicine, 10229-232. https://doi.org/10.2147/PGPM.S140461
Filipski, Kelly K, et al. "Updating the landscape of direct-to-consumer pharmacogenomic testing." Pharmacogenomics and personalized medicine vol. 10 (2017): 229-232. doi: https://doi.org/10.2147/PGPM.S140461
Filipski KK, Murphy JD, Helzlsouer KJ. Updating the landscape of direct-to-consumer pharmacogenomic testing. Pharmgenomics Pers Med. 2017 Aug 22;10:229-232. doi: 10.2147/PGPM.S140461. eCollection 2017. PMID: 28860839; PMCID: PMC5572950.
Copy Download .nbib Format: NLM
Next steps in studying the human microbiome and health in prospective studies, Bethesda, MD, May 16-17, 2017.

Microbiome

Sinha R, Ahsan H, Blaser M, Caporaso JG, Carmical JR, Chan AT, Fodor A, Gail MH, Harris CC, Helzlsouer K, Huttenhower C, Knight R, Kong HH, Lai GY, Hutchinson DLS, Le Marchand L, Li H, Orlich MJ, Shi J, Truelove A, Verma M, Vogtmann E, White O, Willett W, Zheng W, Mahabir S, Abnet C.
PMID: 30477563
Microbiome. 2018 Nov 26;6(1):210. doi: 10.1186/s40168-018-0596-z.

The National Cancer Institute (NCI) sponsored a 2-day workshop, "Next Steps in Studying the Human Microbiome and Health in Prospective Studies," in Bethesda, Maryland, May 16-17, 2017. The workshop brought together researchers in the field to discuss the challenges...

Cite
Sinha R, Ahsan H, Blaser M, et al. Next steps in studying the human microbiome and health in prospective studies, Bethesda, MD, May 16-17, 2017. Microbiome. 2018;6(1):210doi: 10.1186/s40168-018-0596-z.
Sinha, R., Ahsan, H., Blaser, M., Caporaso, J. G., Carmical, J. R., Chan, A. T., Fodor, A., Gail, M. H., Harris, C. C., Helzlsouer, K., Huttenhower, C., Knight, R., Kong, H. H., Lai, G. Y., Hutchinson, D. L. S., Le Marchand, L., Li, H., Orlich, M. J., Shi, J., Truelove, A., Verma, M., Vogtmann, E., White, O., Willett, W., Zheng, W., Mahabir, S., & Abnet, C. (2018). Next steps in studying the human microbiome and health in prospective studies, Bethesda, MD, May 16-17, 2017. Microbiome, 6(1), 210. https://doi.org/10.1186/s40168-018-0596-z
Sinha, Rashmi, et al. "Next steps in studying the human microbiome and health in prospective studies, Bethesda, MD, May 16-17, 2017." Microbiome vol. 6,1 (2018): 210. doi: https://doi.org/10.1186/s40168-018-0596-z
Sinha R, Ahsan H, Blaser M, Caporaso JG, Carmical JR, Chan AT, Fodor A, Gail MH, Harris CC, Helzlsouer K, Huttenhower C, Knight R, Kong HH, Lai GY, Hutchinson DLS, Le Marchand L, Li H, Orlich MJ, Shi J, Truelove A, Verma M, Vogtmann E, White O, Willett W, Zheng W, Mahabir S, Abnet C. Next steps in studying the human microbiome and health in prospective studies, Bethesda, MD, May 16-17, 2017. Microbiome. 2018 Nov 26;6(1):210. doi: 10.1186/s40168-018-0596-z. PMID: 30477563; PMCID: PMC6257978.
Copy Download .nbib Format: NLM
RESPONSE: re: weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

Journal of the National Cancer Institute

Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V.
PMID: 10793119
J Natl Cancer Inst. 2000 May 03;92(9):758. doi: 10.1093/jnci/92.9.758.

No abstract available.

Cite
Gail MH, Costantino JP, Bryant J, et al. RESPONSE: re: weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 2000;92(9):758doi: 10.1093/jnci/92.9.758.
Gail, M. H., Costantino, J. P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., & Vogel, V. (2000). RESPONSE: re: weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. Journal of the National Cancer Institute, 92(9), 758. https://doi.org/10.1093/jnci/92.9.758
Gail, et al. "RESPONSE: re: weighing the risks and benefits of tamoxifen treatment for preventing breast cancer." Journal of the National Cancer Institute vol. 92,9 (2000): 758. doi: https://doi.org/10.1093/jnci/92.9.758
Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V. RESPONSE: re: weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 2000 May 03;92(9):758. doi: 10.1093/jnci/92.9.758. PMID: 10793119.
Copy Download .nbib Format: NLM
Prostate-specific antigen levels and subsequent prostate cancer: potential for screening.

American journal of epidemiology

Helzsouer KJ, Newby J, Comstock GW.
PMID: 18820278
Am J Epidemiol. 2008 Oct 01;168(7):841-4. doi: 10.1093/aje/kwn271.

Prostate-specific antigen levels are increased in men with prostatic disease, including prostate cancer, and have been used clinically to monitor the response of prostate cancer to therapy. More recently, prostate-specific antigen levels, usually in combination with digital rectal examination...

Cite
Helzsouer KJ, Newby J, Comstock GW. Prostate-specific antigen levels and subsequent prostate cancer: potential for screening. Am J Epidemiol. 2008;168(7):841-4doi: 10.1093/aje/kwn271.
Helzsouer, K. J., Newby, J., & Comstock, G. W. (2008). Prostate-specific antigen levels and subsequent prostate cancer: potential for screening. American journal of epidemiology, 168(7), 841-4. https://doi.org/10.1093/aje/kwn271
Helzsouer, Kathy J, et al. "Prostate-specific antigen levels and subsequent prostate cancer: potential for screening." American journal of epidemiology vol. 168,7 (2008): 841-4. doi: https://doi.org/10.1093/aje/kwn271
Helzsouer KJ, Newby J, Comstock GW. Prostate-specific antigen levels and subsequent prostate cancer: potential for screening. Am J Epidemiol. 2008 Oct 01;168(7):841-4. doi: 10.1093/aje/kwn271. PMID: 18820278.
Copy Download .nbib Format: NLM
Correction: vitamin d metabolic pathway genes and pancreatic cancer risk.

PloS one

Arem H, Yu K, Xiong X, Moy K, Freedman ND, Mayne ST, Albanes D, Amundadottir LT, Arslan AA, Austin M, Bamlet WR, Beane-Freeman L, Bracci P, Canzian F, Chanock SJ, Cotterchio M, Duell EJ, Gallinger S, Giles GG, Goggins M, Goodman PJ, Hartge P, Hassan M, Helzlsouer K, Henderson B, Holly EA, Hoover R, Jacobs EJ, Kamineni A, Klein A, Klein E, Kolonel LN, Li D, Malats N, Männistö S, McCullough ML, Olson SH, Orlow I, Peters U, Petersen GM, Porta M, Severi G, Shu XO, Van Den Eeden S, Visvanathan K, White E, Yu H, Zeleniuch-Jacquotte A, Zheng W, Tobias GS, Maeder D, Brotzman M, Risch H, Sampson JN, Stolzenberg-Solomon RZ.
PMID: 26039095
PLoS One. 2015 Jun 03;10(6):e0129983. doi: 10.1371/journal.pone.0129983. eCollection 2015.

No abstract available.

Cite
Arem H, Yu K, Xiong X, et al. Correction: vitamin d metabolic pathway genes and pancreatic cancer risk. PLoS One. 2015;10(6):e0129983doi: 10.1371/journal.pone.0129983.
Arem, H., Yu, K., Xiong, X., Moy, K., Freedman, N. D., Mayne, S. T., Albanes, D., Amundadottir, L. T., Arslan, A. A., Austin, M., Bamlet, W. R., Beane-Freeman, L., Bracci, P., Canzian, F., Chanock, S. J., Cotterchio, M., Duell, E. J., Gallinger, S., Giles, G. G., Goggins, M., Goodman, P. J., Hartge, P., Hassan, M., Helzlsouer, K., Henderson, B., Holly, E. A., Hoover, R., Jacobs, E. J., Kamineni, A., Klein, A., Klein, E., Kolonel, L. N., Li, D., Malats, N., Männistö, S., McCullough, M. L., Olson, S. H., Orlow, I., Peters, U., Petersen, G. M., Porta, M., Severi, G., Shu, X. O., Van Den Eeden, S., Visvanathan, K., White, E., Yu, H., Zeleniuch-Jacquotte, A., Zheng, W., Tobias, G. S., Maeder, D., Brotzman, M., Risch, H., Sampson, J. N., & Stolzenberg-Solomon, R. Z. (2015). Correction: vitamin d metabolic pathway genes and pancreatic cancer risk. PloS one, 10(6), e0129983. https://doi.org/10.1371/journal.pone.0129983
Arem, Hannah, et al. "Correction: vitamin d metabolic pathway genes and pancreatic cancer risk." PloS one vol. 10,6 (2015): e0129983. doi: https://doi.org/10.1371/journal.pone.0129983
Arem H, Yu K, Xiong X, Moy K, Freedman ND, Mayne ST, Albanes D, Amundadottir LT, Arslan AA, Austin M, Bamlet WR, Beane-Freeman L, Bracci P, Canzian F, Chanock SJ, Cotterchio M, Duell EJ, Gallinger S, Giles GG, Goggins M, Goodman PJ, Hartge P, Hassan M, Helzlsouer K, Henderson B, Holly EA, Hoover R, Jacobs EJ, Kamineni A, Klein A, Klein E, Kolonel LN, Li D, Malats N, Männistö S, McCullough ML, Olson SH, Orlow I, Peters U, Petersen GM, Porta M, Severi G, Shu XO, Van Den Eeden S, Visvanathan K, White E, Yu H, Zeleniuch-Jacquotte A, Zheng W, Tobias GS, Maeder D, Brotzman M, Risch H, Sampson JN, Stolzenberg-Solomon RZ. Correction: vitamin d metabolic pathway genes and pancreatic cancer risk. PLoS One. 2015 Jun 03;10(6):e0129983. doi: 10.1371/journal.pone.0129983. eCollection 2015. PMID: 26039095; PMCID: PMC4454722.
Copy Download .nbib Format: NLM
Utilizing SEER Cancer Registries for Population-Based Cancer Survivor Epidemiologic Studies: A Feasibility Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Gallicchio L, Elena JW, Fagan S, Carter M, Hamilton AS, Hastert TA, Hunter LL, Li J, Lynch CF, Milam J, Millar MM, Modjeski D, Paddock LE, Reed AR, Moses LB, Stroup AM, Sweeney C, Trapido EJ, West MM, Wu XC, Helzlsouer KJ.
PMID: 32651214
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1699-1709. doi: 10.1158/1055-9965.EPI-20-0153. Epub 2020 Jul 10.

BACKGROUND: While the primary role of central cancer registries in the United States is to provide vital information needed for cancer surveillance and control, these registries can also be leveraged for population-based epidemiologic studies of cancer survivors. This study...

Cite
Gallicchio L, Elena JW, Fagan S, et al. Utilizing SEER Cancer Registries for Population-Based Cancer Survivor Epidemiologic Studies: A Feasibility Study. Cancer Epidemiol Biomarkers Prev. 2020;29(9):1699-1709doi: 10.1158/1055-9965.EPI-20-0153.
Gallicchio, L., Elena, J. W., Fagan, S., Carter, M., Hamilton, A. S., Hastert, T. A., Hunter, L. L., Li, J., Lynch, C. F., Milam, J., Millar, M. M., Modjeski, D., Paddock, L. E., Reed, A. R., Moses, L. B., Stroup, A. M., Sweeney, C., Trapido, E. J., West, M. M., Wu, X. C., & Helzlsouer, K. J. (2020). Utilizing SEER Cancer Registries for Population-Based Cancer Survivor Epidemiologic Studies: A Feasibility Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(9), 1699-1709. https://doi.org/10.1158/1055-9965.EPI-20-0153
Gallicchio, Lisa, et al. "Utilizing SEER Cancer Registries for Population-Based Cancer Survivor Epidemiologic Studies: A Feasibility Study." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,9 (2020): 1699-1709. doi: https://doi.org/10.1158/1055-9965.EPI-20-0153
Gallicchio L, Elena JW, Fagan S, Carter M, Hamilton AS, Hastert TA, Hunter LL, Li J, Lynch CF, Milam J, Millar MM, Modjeski D, Paddock LE, Reed AR, Moses LB, Stroup AM, Sweeney C, Trapido EJ, West MM, Wu XC, Helzlsouer KJ. Utilizing SEER Cancer Registries for Population-Based Cancer Survivor Epidemiologic Studies: A Feasibility Study. Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1699-1709. doi: 10.1158/1055-9965.EPI-20-0153. Epub 2020 Jul 10. PMID: 32651214; PMCID: PMC7484198.
Copy Download .nbib Format: NLM
Humanizing Big Data: Recognizing the Human Aspect of Big Data.

Frontiers in oncology

Helzlsouer K, Meerzaman D, Taplin S, Dunn BK.
PMID: 32231993
Front Oncol. 2020 Mar 13;10:186. doi: 10.3389/fonc.2020.00186. eCollection 2020.

The term "big data" refers broadly to large volumes of data, often gathered from several sources, that are then analyzed, for example, for predictive analytics. Combining and mining genetic data from varied sources including clinical genetic testing, for example,...

Cite
Helzlsouer K, Meerzaman D, Taplin S, et al. Humanizing Big Data: Recognizing the Human Aspect of Big Data. Front Oncol. 2020;10:186doi: 10.3389/fonc.2020.00186.
Helzlsouer, K., Meerzaman, D., Taplin, S., & Dunn, B. K. (2020). Humanizing Big Data: Recognizing the Human Aspect of Big Data. Frontiers in oncology, 10186. https://doi.org/10.3389/fonc.2020.00186
Helzlsouer, Kathy, et al. "Humanizing Big Data: Recognizing the Human Aspect of Big Data." Frontiers in oncology vol. 10 (2020): 186. doi: https://doi.org/10.3389/fonc.2020.00186
Helzlsouer K, Meerzaman D, Taplin S, Dunn BK. Humanizing Big Data: Recognizing the Human Aspect of Big Data. Front Oncol. 2020 Mar 13;10:186. doi: 10.3389/fonc.2020.00186. eCollection 2020. PMID: 32231993; PMCID: PMC7082327.
Copy Download .nbib Format: NLM
The Delicate Balancing Act of Childhood Cancer Treatment-Not Too Much but Not Too Little.

Journal of the National Cancer Institute

Gallicchio L, Helzlsouer KJ.
PMID: 33002106
J Natl Cancer Inst. 2021 May 04;113(5):509-510. doi: 10.1093/jnci/djaa153.

No abstract available.

Cite
Gallicchio L, Helzlsouer KJ. The Delicate Balancing Act of Childhood Cancer Treatment-Not Too Much but Not Too Little. J Natl Cancer Inst. 2021;113(5):509-510doi: 10.1093/jnci/djaa153.
Gallicchio, L., & Helzlsouer, K. J. (2021). The Delicate Balancing Act of Childhood Cancer Treatment-Not Too Much but Not Too Little. Journal of the National Cancer Institute, 113(5), 509-510. https://doi.org/10.1093/jnci/djaa153
Gallicchio, Lisa, and Helzlsouer, Kathy J. "The Delicate Balancing Act of Childhood Cancer Treatment-Not Too Much but Not Too Little." Journal of the National Cancer Institute vol. 113,5 (2021): 509-510. doi: https://doi.org/10.1093/jnci/djaa153
Gallicchio L, Helzlsouer KJ. The Delicate Balancing Act of Childhood Cancer Treatment-Not Too Much but Not Too Little. J Natl Cancer Inst. 2021 May 04;113(5):509-510. doi: 10.1093/jnci/djaa153. PMID: 33002106; PMCID: PMC8096363.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 20 entries